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Abstract
Background Clinical pharmacy services have potential to contribute significantly to the multidisciplinary team providing safe, 
effective and economic care for patients. Given recent practice developments (e.g. polypharmacy reviews and pharmacist 
prescribing) there is a need to provide a current synthesis of the evidence base for characteristics and outcomes of clinical 
pharmacy practice in chronic kidney disease patients. Aim of the review To critically appraise, synthesise and present the 
available evidence of the characteristics (structures and processes) and outcomes of clinical pharmacy practice as part of 
the multidisciplinary care of patients with chronic kidney disease. Method PubMed, International Pharmaceutical Abstracts 
(IPA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline and Scopus were searched for peer 
reviewed papers using improved search strategy. Included studies were quality assessed using Downs and Black tool for 
controlled studies and the mixed methods appraisal tool for all controlled and non-controlled studies. Data were extracted and 
synthesised using a narrative approach. Screening, quality assessment and data extraction were performed by two independent 
researchers. Ethics approval was not required. Results Forty-seven studies were identified from a variety of countries, with 
31 based in a hospital setting. Controlled study designs were employed in 20, with only ten of these using randomisation. 
Resources available for service provision were poorly reported in all papers. Positive impact on clinical outcomes included 
significant improvement in parathyroid hormone, blood pressure, haemoglobin and creatinine clearance. Pharmacists identi-
fied 5302 drug related problems in 2933 patients and made 3160 recommendations with acceptance rates up to 95%. Impact 
on humanistic outcomes was shown through improvement in health related quality of life and patient satisfaction. Economic 
benefits arose from significant cost savings through pharmaceutical care provision. Conclusion While there is some evidence 
of positive impact on clinical, humanistic and economic outcomes, this evidence is generally of low quality and insufficient 
volume. While the existing evidence is in favour of pharmacists’ involvement in the multidisciplinary team providing care 
to patients with chronic kidney disease, more high-quality research is warranted.
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Impacts on practice
• Understanding fully the structures, processes and rel-
evant outcomes associated with clinical roles of phar-
macists is essential to make best use of resource for 
optimal patient care.
• There has been a significant volume of research of the 
clinical role of pharmacists in Chronic Kidney Disease, 
but it is of limited detail and quality.
• There is a need for agreed standard sets of outcomes 
for clinical pharmacy practice and research in chronic 
kidney disease.
Introduction
Chronic Kidney Disease (CKD) continues to be a global 
concern with a high risk of mortality, frequent hospitalisa-
tion and reduced life expectancy [1]. Most patients have 
co-morbid conditions such as cardiovascular and mineral 
bone diseases [2]. Clinical pharmacy services have the 
potential to contribute significantly to the multidiscipli-
nary team providing safe, effective and economic care [3]. 
Key clinical pharmacy roles in the multidisciplinary care 
of CKD patients were described by two renal pharmacy 
consultants Mason and Bakus in 2010 [4]. These roles 
included specific areas such as managing anaemia, renal 
mineral bone disease and hypertension, as well as more 
general medicines selection and review [4]. Another major 
role pharmacists can play is to contribute to renal drug 
cost management [5]. An emerging role is the potential for 
the pharmacist to prescribe and modify medicines, which 
has now been implemented into practice in the United 
Kingdom (UK), United States (USA) and New Zealand 
[6]. There is a need to establish the evidence base of the 
impact of clinical pharmacy in the care of CKD patients. 
In 2012, Salgado et  al. published a systematic review 
which included synthesis of the peer reviewed literature up 
to March 2010 [7]. The original review identified 37 stud-
ies (38 articles), involving 4743 participants. Majority of 
the papers were of uncontrolled design (80%) [7]. Twenty-
one articles (55.3%) reported outcome measures and pro-
cess indicators, 4 (10.5%) reported only outcome meas-
ures, thirteen (34.2%) reported only process indicators and 
none reported structures [7]. Pharmacists identified 2683 
drug-related problems in 1209 patients. The results from 
controlled studies (average quality score 0.57, SD = 0.10) 
reported that pharmacists’ interventions reduced all-cause 
hospitalisations, reduced the incidence of end-stage renal 
disease or death in patients with diabetic nephropathy, 
improved management of anaemia, blood pressure, cal-
cium and phosphate parameters and lipid management [7]. 
The uncontrolled studies included in the original review 
shown positive impact of pharmacists’ interventions on 
the reduction of transplant rejections and fewer adverse 
events [7]. The reviews main limitations were selection 
and language bias which might affect the quality of the 
systematic review. Salgado et al. concluded that the evi-
dence of pharmacists’ interventions in patients with CKD 
is scarce, of variable quality and with heterogeneous out-
comes [7]. Since the publication of the original review 
by Salgado et al., the prescribing practice has continually 
developed with new services and models of care being 
developed and embedded into clinical pharmacy practice. 
Hence, there is a need to update and extend the review. 
Given developments in clinical pharmacy globally, it is 
likely that further research has been reported thus an up-
to-date synthesis is warranted.
Aim of the review
The aim of this review was to critically appraise, synthesise 
and present the available evidence for the structures, pro-
cesses and related outcomes of clinical pharmacy practice 
as part of the multidisciplinary care of patients with CKD. 
The specific review questions were:
• What clinical pharmacy practice related resources (struc-
tures, e.g. the multidisciplinary team, clinical pharmacy 
skill mix and time allocation) are in place and how are 
these matched to healthcare needs and demands to ena-
ble provision of care to chronic kidney disease (CKD) 
patients?
• What activities are performed (processes, e.g. medication 
review, prescribing) to care for patients with CKD, how 
and when are they performed?
• What are the outcomes of the structure and the processes 
on the effectiveness (Economic, Clinical, and Humanistic 
Outcomes (ECHO) model) [8] of care provided?
Method
Data sources
The systematic review protocol was registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO) (PROSPERO 2017 CRD42017065258). The 
protocol was constructed in accordance with PRISMA-
P (Preferred Reporting Items for Systematic review and 
Meta-Analysis Protocols) standards [9], and the review con-
ducted and reported in accordance with PRISMA (Preferred 
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Reporting Items for Systematic Review and Meta-Analysis) 
standards [10].
The Cochrane database was searched to identify any rel-
evant systematic reviews. An electronic search of relevant 
databases (PubMed, International Pharmaceutical Abstracts 
(IPA), Cumulative Index to Nursing and Allied Health Lit-
erature (CINAHL), Medline and Scopus) was conducted 
from March 2010 to December 2018 thus providing an 
update on the review of Salgado et al. [7]. The search was 
carried out using Medical Subject Headings (MeSH) and 
other appropriate subject headings and text words. Scoping 
searches were conducted prior to finalising the search strat-
egy. Boolean operators such as truncations (*), wild cards 
($), adjacent search options (e.g. adj2) were used where rel-
evant. The following grouped terms were initially searched 
separately then in combination by two independent review-
ers (FA & SC). The primary search was conducted using the 
improved search strategy of the same terms as the original 
review as follows:
PubMed, IPA, CINAHL: (“pharmaceutical services” 
[MH+] OR “pharmacy” [MH+] OR “Pharmacies” [MH] 
OR “Pharmacists” [MH] OR “clinical pharmacist*” [TI/
AB/SU] OR “clinical pharmacy” [TI/AB/SU] OR “clini-
cal pharmacies” [TI/AB/SU] OR “pharmacist*” [TI/AB/
SU] OR “pharmaceutical services” [TI/AB/SU] OR “phar-
macies” [TI/AB/SU] OR “pharmacy” [TI/AB/SU]) AND 
(“kidney diseases” [MH+] OR “renal replacement therapy” 
[MH+] OR “proteinuria” [MH+] OR “CKD” [TI/AB/SU] 
OR “nephropathy” [TI/AB/SU]).
Scopus:
(“Pharmaceutical care” [TI/ABS/KEY] OR “Pharmacist” 
[TI/ABS/KEY] OR “Clinical pharmacy” [TI/ABS/KEY]) 
AND (“Chronic Kidney Disease” [TI/ABS/KEY] OR “Renal 
replacement Therapy” [TI/ABS/KEY] OR “Haemodialysis” 
[TI/ABS/KEY] OR “Kidney failure” [TI/ABS/KEY]). The 
bibliography list of included studies was reviewed to further 
identify additional references.
Study selection and data extraction
Only quantitative studies (randomised and non-randomised 
controlled and uncontrolled trials, cohort studies and before 
and after evaluations) published in peer-reviewed journals 
were included in the review. Papers published in English and 
focusing on researching clinical pharmacy practice and the 
role of the pharmacist in managing patients with CKD were 
included. Studies not addressing the topic, literature based 
only on conceptual models, i.e. lacking empirical evidence, 
grey literature including conference proceedings, abstracts 
and unpublished studies were excluded. Observational stud-
ies were excluded since they did not address the aim of this 
review.
Title and abstract screening and quality assessment for 
inclusion were conducted independently by two reviewers 
(FA and SC), with any disagreements resolved by discus-
sion with a third independent reviewer (DS).
Quality assessment
An independent, duplicate quality assessment of each 
study was undertaken (DS, TJ, FA & SC). All controlled, 
uncontrolled and descriptive studies were assessed using 
the mixed methods appraisal tool (MMAT), a validated 
and unique tool for appraising different types of study 
designs [11]. All controlled studies included in this review 
were additionally assessed for quality using the Downs 
and Black’s method in line with the original review [12], 
a validated tool with a scoring scale consisting of 27 ques-
tions grouped into five domains (reporting, external valid-
ity, bias, confounding and power). The total score is 32 and 
is expressed as rates, the higher the score the better the 
quality of the paper in terms of methodology (maximum 
is 1) [12]. To classify scores, the approach of Machado 
et al. was applied [13] (i.e. < 0.5 was considered ‘weak’, 
0.5–0.69 were ‘fair’, 0.7–0.79 ‘good’ and 0.8–1.0 ‘very 
good’).
Data extraction
Data extracted included: primary author, year of publica-
tion, aim/objectives, design, duration, setting, participants, 
pharmacist interventions, key findings or main outcomes 
and conclusion. Structures, processes and outcomes were 
adapted from Donabedian’s quality of care model [14]. 
Structure was defined as the ‘resources required for the 
pharmacist to be able to provide care to renal patients such 
as requiring special training, availability of policies and 
procedures for practice etc’. Process was defined as ‘the 
activities that are performed by the pharmacist on a daily 
basis or on specific intervals and how and when they are 
performed. These activities may include: daily clinical 
rounds, involvement in patients’ management plans, medi-
cation reviews, therapeutic recommendations and phar-
macist prescribing. Outcome measures included clinical 
outcomes such as: clinical parameters, medication-related 
adverse events, mortality and morbidities, humanistic out-
comes such as: quality of life and economic outcomes such 
as: rate of hospitalisation and cost of inappropriate thera-
pies. In addition, pharmacists’ intervention was defined in 
the previous review as “any action with the aim of modify-
ing the process of use of drugs, either in patients’ activities 
or in medical or health care practitioners’ activities” [7].
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Data synthesis
Due to heterogeneity in the data obtained from the included 
papers (type of patients, study design, outcomes measured), 
only descriptive and narrative synthesis was possible. All 
findings were considered by two independent reviewers to 
ensure robustness and consistency in execution of the review 
process.
Results
Study selection and data extraction
No systematic reviews were identified from the Cochrane 
database and no additional primary studies were identified 
from the bibliography lists of included studies.
Databases searches identified 4140 potential articles to 
screen further for eligibility (Fig. 1). Only 47 articles met 
the inclusion criteria and after quality assessment were of 
a standard deemed acceptable for inclusion in the review.
Quality assessment
The Downs and Black’s mean score of the 20 controlled 
studies was 0.557 (SD = 0.075). All papers presented ‘fair’ 
quality with the exception of four that scored < 0.5 and was 
therefore considered ‘weak’ quality. The quality assessment 
of all the included studies using the MMAT tool for the ran-
domised (n = 10), non-randomised (n = 20) and descriptive 
studies (n = 17) are shown in Figs. 2, 3 and 4.  
Data extraction
Tables 1 and 2 detail the data extraction characteristics of 
controlled and uncontrolled studies included in the system-
atic review [15–61].
Fig. 1  PRISMA Chart describ-
ing study retrieval and selection
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Study characteristics
The 47 studies were carried out in a variety of geographic 
locations: USA (n = 10), Iran (n = 5), India (n = 7), France 
(n = 3), Spain (n = 3), Jordan (n = 2), China (n = 2), Japan 
(n = 3), Singapore (n = 2), Nigeria, Taiwan, Australia, Saudi 
Arabia, Germany, Netherlands, Indonesia, Norway, Canada 
and the UK (n = 1 in each country). Two studies from 2008 
to 2009 were not included in the systematic review of Sal-
gado et al. [7], hence were considered as part of this review. 
Thirty-one studies were conducted in hospital settings 
(wards, intensive care units (ICU), clinics, departments and 
dialysis units) and 16 in primary care settings, including 
clinics and community pharmacies. The follow-up time in 
all included papers ranged from 4 weeks to 24 months with 
a mean of 9.4 (standard deviation, SD = 5.08) months, with 
four studies with unclear duration.
The majority of studies (n = 27) used an uncontrolled 
study design, 21 prospective and six retrospective. The 
remaining 20 were controlled, ten of which were randomised 
Fig. 2  Stacked bar chart representing quality of quantitative Randomized Controlled Trials (n = 10). The % values above represents the propor-
tion for each response as agreed between reviewers for the papers included for each study design
Fig. 3  Stacked bar chart representing quality of quantitative non-randomized studies (n = 20). The % values above represents the proportion for 
each response as agreed between reviewers for the papers included for each study design
Fig. 4  Stacked bar chart representing quality of quantitative descriptive studies (n = 17). The % values above represents the proportion for each 
response as agreed between reviewers for the papers included for each study design
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and ten non-randomised. According to Thomson Reuters 
Journal Citation Report at the time of publication the median 
impact factor of the journals of articles included was 1.348 
(IQR 0.52–2.01), n = 45, two journals did not have an impact 
factor at the time of publication.
Patient mean age was 46.7–84.9 years, with five stud-
ies failing to report age [23, 29, 31, 46, 60]. Of the total of 
11,122 patients from all studies, 9151 were at various stages 
of chronic kidney disease not on dialysis, 1036 were haemo-
dialysis (HD) dependent, 533 receiving other forms of renal 
replacement therapies such as continuous renal replacement 
therapy (CRRT) or continuous veno-venous hemofiltration 
(CVVH), and 402 were transplant patients.
Outcomes were reported in 37 papers, with 25 of these 
(67.6%) also reporting details of the processes of care, 
and four (10.8%) reporting structures, processes and out-
comes. Outcomes reported were: clinical only (17, 45.9%), 
economic with linked clinical (5, 13.5%), humanistic with 
linked clinical (4, 10.8%), humanistic only (2, 5.4%) and 
economic only (2, 5.4%). The 10 remaining papers did not 
report outcomes measures with one (2.1%) that reported 
structure and process indicators only and 9 (19.1%) reported 
process indicators only.
Resources for care provision: structures
Structures were poorly reported in all studies, with only two 
giving some details of multidisciplinary team involvement 
[52, 61], while, none on the pharmacist skill mix or time 
allocation. The only aspect of structures reported relating to 
training which was given in five studies. In one, pharmacists 
and pharmacy residents were engaged in a two-week training 
of literature review and patient assessments [35]. A com-
munity pharmacist based study described a workshop cov-
ering clinical presentations of CKD, managing drug-related 
problems and discussing patient cases [48]. Similar training 
was described for community pharmacists, [18] and hospital 
clinical pharmacists [16], to enable them to identify patients 
with renal insufficiency and perform dose adjustments. A 
four session course to all members of the multidisciplinary 
team prior to the study was described in one article [61].
Characteristics of clinical pharmacy practice: 
processes
All studies provided some description of the processes 
undertaken by the pharmacists, although the detail pro-
vided varied considerably and was generally lacking. The 
majority of processes (often labelled as interventions) 
included medication chart review to identify any drug-
related problems (DRPs) [15–31]. Many studies reported 
pharmacists’ interventions in: modifying drug doses and 
recommending new pharmacotherapy; [16, 19, 21–23, 
25–27, 29, 30, 32–40, 52, 59]; interacting with a member 
of the multidisciplinary team; [15–17, 19–21, 23–25, 27, 
31, 32, 34–38, 40–43] requesting and monitoring labo-
ratory parameters; [15, 23, 25, 27, 33, 34, 36, 37, 43] 
assessing appropriateness of medications prescribed for 
hospitalised patients at each point of care; [17, 22, 29, 
30, 35–38, 40, 57]. Fewer studies described pharmacist 
processes at out-patient, pharmacist-led clinics relating 
to the management of specific CKD complications, such 
as anaemia; [34, 39, 44] hypertension and diabetes; [54] 
managing hypertension through telemedicine; [41] opti-
mising dyslipidaemia management; [37, 45] improving 
haemoglobin A1c levels (HbA1c); [43] and emphasising 
smoking cessation. [37, 43] Development of protocols and 
compiling and updating guidelines were also described in 
two studies [22, 34]. Performing medication reconciliation 
[46]; providing patient medication counselling, education 
on disease status or medication, conducting motivational 
interviews to improve adherence were also reported [15, 
25, 27, 29, 30, 34, 36, 37, 42, 43, 47–50, 55, 57, 58, 60]. 
A number of studies reported pharmacists’ participation in 
ward rounds [17, 22, 35, 37, 38, 40], providing educational 
sessions to healthcare professionals [22, 34] and perform-
ing activities such as medication use evaluations [34]. 
There were no reports of pharmacist prescribing activi-
ties; one study described the process of deprescribing to 
optimise medication use [59].
Fewer studies provided any data on time spent on specific 
activities. Interaction time between pharmacist and patients 
were reported in two studies, varying from 15 to 30 min [43, 
50] and the timeframe in which the services were provided 
ranged from daily [35–38, 40] to every three months [47].
Across all studies, the pharmacists identified 5302 drug-
related problems in 2933 patients. Pharmacists made 3160 
recommendations to healthcare professionals with an accept-
ance rate varying from 33.3% in a community setting; [16] 
46.43% in a dialysis unit; [59] to around 95% in hospital 
settings [17, 24, 42, 51, 52, 57]. Only three studies reported 
the clinical significance of recommendations. Of these 26% 
were of moderate to [29], 48.8% of major clinical signifi-
cance [51] and 47% serious severity [20].
A pharmacist-based quality improvement programme 
consisting of pharmacists’ interactions with the patients and 
electronic collaboration with the physicians was associated 
with a significant improvement in the measurement of PTH 
during the study period [15]. Pharmacists’ interventions led 
to medication therapy modifications [16–21, 24–29, 31, 33, 
37, 42, 46] and resolving medication record discrepancies 
[46, 57]. Patients’ compliance with ongoing blood pressure 
(BP) monitoring post kidney transplantation was signifi-
cantly improved with pharmacists’ input [41]. Counselling 
by pharmacists significantly improved medication adherence 
in patients with CKD [47, 50, 60].
661International Journal of Clinical Pharmacy (2019) 41:630–666 
1 3
Clinical outcomes
The final column of Tables 1 and 2 titled ‘Main outcomes 
achieved’ provides a detailed summary of main results and 
statistical significance values related to each of the studies 
summarised below. Clinical outcomes only were reported 
in (n = 17) studies. A pharmacist-based quality improve-
ment programme in a pragmatic randomised controlled 
study reported that patients in the intervention arm were 
prescribed more classes of antihypertensive medications 
than those in the control arm [15]. In a 6-month cluster 
randomised trial, pharmacists attending a structured train-
ing and communication-network programme (ProFil) and 
managing hypertension in CKD patients demonstrated 
larger reduction in systolic blood pressure (BP) of the 
intervention group compared to the usual care group [48].
Intervention in the management of BP in CKD and hae-
modialysis resulted in achieving target BP in the inter-
vention versus the control group [32, 54, 55], significant 
reductions in mean systolic and diastolic BP in a group of 
kidney transplant recipients [41], and significant reduc-
tion in systolic and diastolic BP in diabetic nephropathy 
[43]. Only one article showed that pharmacists’ interven-
tion in an intensive care unit (ICU) setting reduced the 
length of ICU stay [38]. Another study reported reduc-
tion in the length of stay in the intervention group by 
1.3 days (p < 0.001) and reduced unplanned admission by 
27% (p = 0.047) [52]. One further study showed no dif-
ference of pharmacists’ intervention compared to usual 
care on hospital readmission outcomes [57]. Pharmacists 
were also involved in the monitoring of kidney function 
in patients with CKD and demonstrated significant differ-
ences in measuring CrCl between discharge and admission 
[36]. However, one study demonstrated no difference in 
the mean serum creatinine or estimated glomerular fil-
tration rate (eGFR) between the intervention and control 
groups [58]. A retrospective controlled study reported 
improvement in eGFR, uric acid, cholesterol and HbA1c in 
the intervention group compared to the control group after 
multidisciplinary care, however, pharmacists’ contribution 
to the care was not clearly reported [61].
Four studies gave outcomes of pharmacists managing 
anaemia in CKD patients [34, 39, 44, 55], with significant 
haemoglobin values within target range in pharmacist-led 
clinic. Time to achieve target haemoglobin was 28 days in 
the pharmacist-managed group compared with 41 days in 
the usual care group [44]. While the proportion of patients 
achieving target haemoglobin was not significant, pharma-
cist intervention significantly improved haemoglobin and 
iron monitoring by improving compliance to therapy [44]. 
Pharmacist counselling significantly improved haemoglobin 
levels in one study [34], with haemoglobin concentration 
and Transferrin saturation (TSAT%) increasing significantly 
and serum ferritin reaching target values in a prospective 
uncontrolled study [23].
An uncontrolled study of the impact of on managing sec-
ondary complications of haemodialysis patients resulted in 
significantly increased median serum calcium in those with 
hypocalcaemia and decreased values in hypercalcaemia, 
a decline in serum phosphate in patients with hyperphos-
phataemia, and an increase and decrease in serum iPTH in 
patients with sub-optimal and supra-optimal levels respec-
tively [23].
Pharmacists’ interventions in a pragmatic, cluster ran-
domised study improved screening of proteinuria between 
an interventions compared to control group [45]. A non-
randomised controlled study of pharmacist involvement in 
a monitoring program for CKD reported significant differ-
ences in CrCl between discharge and admission in both the 
control and intervention groups [36].
Humanistic outcomes
In a cluster, randomised study health related quality of life 
(HRQoL) improved significantly compared to control in a 
group of haemodialysis patients receiving pharmacist inter-
vention over a 6-month period [30]. In a non-randomised 
controlled study, HRQoL domains were not significantly 
impacted by the additional pharmacist care in kidney trans-
plants [47]. A multicentre RCT reported significant improve-
ment in HRQoL scores in the intervention group compared 
to control [53].
Patient satisfaction reported in two randomised controlled 
studies: 92% of patients had positive feelings about pharma-
cists’ involvement in their care and felt that the pharmacist 
provided beneficial information [15] and 43% of patients 
were ‘very satisfied’ with the care received and were willing 
to receive future care from the pharmacist [45]. A cross-
sectional prospective study demonstrated that patients were 
greatly satisfied with the intervention [58].
Economic outcomes
Only seven studies reported economic outcomes resulting 
from pharmacist input [22, 35, 38–40, 44, 56]. One study 
reported that pharmacists in the ICU could contribute to 
significant cost savings in septic patients, with antimicro-
bial prescribing efficiencies accounted for 34.7% of total 
savings [38]. In a study investigating an ICU pharmacist 
dosing adjustment programme, the mean ICU hospitalisation 
costs per patient decreased significantly with total savings of 
2669.5 USD per patient [40]. Jiang et al. demonstrated that 
pharmacist dosing adjustment resulted in drug cost savings 
per patient of 2345.98 USD with antibiotics accounting for 
64.5% of all cost savings. The presence of an ICU phar-
macist resulted in 2346 USD savings per patient receiving 
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continuous renal replacement therapy [35]. Debenito et al. 
reported that the mean weekly dose of erythropoiesis-stimu-
lating agents (ESAs) was significantly less in the pharmacist-
managed group than the usual care group and the annualised 
ESA cost per patient reduced by 1288 USD [44], whereas, 
Aspinall et al. reported lower average dose of darbepoetin in 
the pharmacist-managed ESA clinic compared to the usual 
care [39]. Mousavi et al. showed that the cost per patient 
for inappropriate stress ulcer prophylaxis administration 
in patients with insufficient renal function was reduced by 
pharmacists’ intervention [22]. A multicentre RCT reported 
that pharmaceutical care costed more per quality adjusted 
life year (QALY) gained compared to usual care [56].
Discussion
There are a number of important key findings that have 
arisen from this review and these are outlined below. Forty-
seven new studies have been published in the intervening 
8 year period since a previous similar review [7]. Ten of 
these are of a ‘gold standard’ RCT design and the quality 
of the controlled studies included is generally poor. Struc-
tures and processes were very poorly reported and none of 
the studies included consideration of pharmacist prescrib-
ing—which is considered in several countries, where it has 
been implemented, to be a significant advance in pharmacy 
practice. The process indicators in the original review [7] 
and this review were very similar but this review identified 
papers with clear shift from only identifying drug-related 
problems to more involvement of the pharmacist in medica-
tion therapy management. Most of the studies in this review 
continue to focus on and report details of DRPs as an indi-
cator of the process of pharmacy practice. Some of these 
considered the clinical significance of these DRPs but this 
was not universal. Less focus on clinical, humanistic and 
economic outcomes was observed in majority of the papers 
in both reviews.
Many of the uncontrolled studies had a variety of quality 
deficiencies including; lack of comprehensive explanation 
of the pharmacists’ intervention, under-reporting of adverse 
events and insufficient information to allow reproduc-
tion of the study for interested readers. Few studies lacked 
some important information leading to poor scoring of the 
study, such as lack of clarity in stating the study aim, [35] 
the number of participants, the population from where the 
sample was drawn, duration of the data collection or the 
study period, frequency of follow-up, and some studies were 
unable to clearly state the distribution of the confounders in 
both groups [15, 22, 30, 35, 39, 45].
The majority of the 20 controlled studies were of ‘fair’ 
quality with the exception of four that were considered 
‘weak’ [22, 55, 56, 58]. High quality RCTs with low levels 
of bias generate the highest level of evidence [62]. However, 
the availability of quality evidence in this area is limited 
with only 5 RCTs were included in this review and 4 in a 
previous review by Salgado et al. [7]. The RCTs in both 
reviews lacked sufficient information on the randomisation 
process, in addition to poor detail on any blinding process 
of the care-giver and the care-receiver (however, it might be 
a challenge to blind in some study designs) so jeopardising 
the quality of these studies [63]. It is therefore evident that 
there has been a limited amount of high quality research 
published for the benefits of clinical pharmacy practice in 
CKD. There is particularly a paucity of evidence from RCTs 
offering a robust evidence base for practice. Despite this 
criticism there is a growing body of information in relation 
to some aspects of clinical pharmacy practice that offers 
some insights to the developing quality of services provided 
making real and significant differences to the outcomes of 
patients. This, however, needs to be verified through even 
more robust RCTs that are better resourced, designed and 
executed.
The gathering of more gold standard evidence such as 
RCTs is essential to enable measuring the impact of clinical 
pharmacists’ intervention in patients with CKD compared 
to standard care. Furthermore, there is an identified need to 
carry out studies with explicit details and accurate defini-
tions including the setting, the participants, the randomisa-
tion process and the interventions of interest.
It is of paramount importance that detailed descriptions 
of the interventions, in terms of structures and processes 
and outcomes, are included in publications to allow them 
to be reproduced and for readers to consider the studies 
within the context of their own practice [64]. Most papers 
lacked sufficient details of the clinical pharmacy practices so 
making it difficult to fully understand the activity. Without 
full insight to practice it is difficult to fully understand the 
context and characteristics of practice and so reproduce the 
structures and processes in wider settings. This is not just 
a deficiency of studies in CKD since a study by Schroter 
et al. to assess the replicability of published clinical inter-
ventions, in a variety of clinical settings, reported that 57% 
of the studies had insufficient description of the interven-
tion of interest to make it replicable [65]. A tool produced 
by Correr et al. to address the lack of intervention descrip-
tions in clinical pharmacy research (Descriptive Elements of 
Pharmacist Intervention Characterization Tool) DEPICT is 
a validated instrument for accurately describing the details 
of pharmacist interventions performed as part of clinical 
pharmacy practice [66]. This tool could be used as a guid-
ance to structurally describe the intervention of interest in 
pharmacy practice research.
Additionally it should be noted that in CKD there are 
no studies that have specifically investigated prescrib-
ing as part of clinical pharmacy practice and there are no 
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full description of structure, processes and outcomes as 
they relate to prescribing practice. A systematic review 
by Tesfaye et al. published in 2017 of the prevalence of 
inappropriate prescribing and the impact of pharmacists’ 
interventions reported significant reduction in inappro-
priate prescribing when physicians received immediate 
concurrent feedback from a clinical pharmacist [67]. The 
review showed minimal involvement of the pharmacist 
in the role of prescribing for patients with CKD. Despite 
the increased recognition of prescribing models such as 
independent, supplementary or collaborative [6], there 
was limited published evidence to lead to the best practice 
model for prescribing.
There is also a need to stimulate more of a research cul-
ture within clinical pharmacy practice. A paper by Peter-
son et al. reported that lack of time, lack of opportunities, 
lack of training and never being asked to participate in a 
research were major barriers for pharmacists’ engagement 
in research [68]. A systematic review by Awaisu et al. con-
cluded that pharmacists are aware of the value of research 
to enable them advance pharmacy practice and indicate 
their willingness to be involved in independent research 
and in practice-based research networks. However, lack 
of time, training and support were the main barriers [69].
A strength for this review is that the protocol was peer 
reviewed and registered with PROSPERO. The protocol 
was devised in accordance with PRISMA-P (Preferred 
Reporting Items for Systematic review and Meta-Analysis 
Protocols) standards [9] and the systematic review was 
conducted and reported in accordance with PRISMA (Pre-
ferred Reporting Items for Systematic Review and Meta-
Analysis) standards [10]. In terms of limitations, publi-
cation bias could potentially affect the selecting process 
of the articles, since no study was identified to show the 
negative impact of clinical pharmacy services in caring for 
patients with CKD. One further limitation is the exclusion 
of papers in languages other than English potentially lead-
ing to the omission of relevant papers.
In conducting RCTs, it has been recognised that it is 
vital to be careful in the selection and recording of out-
comes to build up a coherent dataset [70–73]. Moreover, 
consistency in the use of outcomes will aid future users 
of the services and those involved in resource alloca-
tion, planning and implementation of clinical pharmacy 
services [72]. It is evident from this review that where 
RCTs were conducted, there was no consistency in the 
selection and reporting of outcomes. These issues could 
be addressed with the development and application of 
agreed standardised sets of outcomes [73]. Research on 
core outcome set definitions for clinical pharmacy prac-
tice is ongoing in many areas such as polypharmacy [74] 
but this appears to be lacking in CKD, which could be a 
potential area of work in the future.
Conclusion
There is some evidence for the outcomes of pharmacists’ 
intervention in patients with CKD but this is generally of 
low quality and insufficient volume. The controlled studies 
in this systematic review showed that pharmacist inter-
ventions improved patients’ clinical outcomes such as Hb 
levels, CrCl, PTH and calcium levels. However, these stud-
ies lacked detail on reporting of the humanistic outcomes 
and there remains a paucity of evidence demonstrating 
economic impact of pharmacists’ interventions.
There is some evidence since the last review that shows 
positive contributions of pharmacists’ involvement in the 
multidisciplinary team to provide care to patients with 
CKD. This includes evidence on the structure, processes 
of care and the outcomes of pharmacists’ intervention in 
patients with CKD. More high-quality research in this area 
is warranted.
Acknowledgements Ms Tesnime Jebara for input to quality assessment 
of papers. Mr Hamed Al Naamani for production of graphs and figures 
and general technical support in production of the manuscript.
Authors’ contributions All authors were involved in all aspects of this 
work including; conception and design, analysis and interpretation of 
data, drafting and revising the article, providing intellectual content 
and final approval of the version to be published.
Funding None.
Conflicts of interest None of the authors has any financial interests or 
connections, direct or indirect, or other situations that might raise the 
question of bias in the work reported or the conclusions, implications 
or opinions stated. In addition, the authors confirm that results pre-
sented in this paper have not been published previously in whole or 
part, except in abstract format.
Ethics approval The Ethics panel of the School of Pharmacy & Life 
Sciences, Robert Gordon University indicated that ethics approval was 
not required for this systematic review.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. KDIGO clinical practice guideline for the evaluation and 
Management of chronic kidney disease. [online] Belgium: the 
International Society of Nephrology. http://www.kdigo .org/clini 
cal_pract ice_guide lines /pdf/CKD/KDIGO _2012_CKD_GL.pdf 
(2013). Accessed 07 Aug 2017.
664 International Journal of Clinical Pharmacy (2019) 41:630–666
1 3
 2. Crockell YJ. Management of chronic kidney disease: an empha-
sis on delaying disease progression and treatment options. For-
mulary. 2012;47(6):228–30.
 3. McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, Dixon 
DL, et al. Collaborative drug therapy management and com-
prehensive medication management. Pharmacotherapy. 2015, 
35(4), e39–50. https ://doi.org/10.1002/phar.1563.
 4. Mason NA, Bakus JL. Strategies for reducing polypharmacy and 
other medication‐related problems in Chronic Kidney Disease. 
Semin Dial. 2010; 55–1.
 5. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact 
of clinical pharmacy services on renal transplant patients’ com-
pliance with immunosuppressive medications. Clin Transplant. 
2001;15(5):330–6.
 6. Royal pharmaceutical society. A competency framework for all 
prescribers. https ://www.rphar ms.com/Porta ls/0/RPS%20doc 
ument %20lib rary/Open%20acc ess/Profe ssion al%20sta ndard s/
Presc ribin g%20com peten cy%20fra mewor k/presc ribin g-compe 
tency -frame work.pdf (2016). Accessed 23 Jan 2017.
 7. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Phar-
macists’ interventions in the management of patients with chronic 
kidney disease: a systematic review. Nephro Dial Transplant. 
2012;27(1):276–92.
 8. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and 
humanistic outcomes: a planning model for pharmacoeconomic 
research. Clin Ther. 1993;15:1121–32.
 9. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew 
M, et al. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 
2015;4(1):1. https ://doi.org/10.1186/2046-4053-4-1.
 10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred report-
ing items for systematic reviews and meta-analyses: the PRISMA 
statement. Int J Surg. 2010;8(5):336–41.
 11. Pluye P, Robert E, Cargo M, Bartlett G, O’Cathain A, Griffiths 
F, et al. Proposal: a mixed methods appraisal tool for systematic 
mixed studies reviews. [online]. Montreal: McGill University 
http://mixed metho dsapp raisa ltool publi c.pbwor ks.com/w/file/
fetch /84371 689/MMAT%20201 1%20cri teria %20and %20tut orial 
%20201 1-06-29upd ated2 014.08.21.pdf (2011). Accessed 03 Aug 
2017.
 12. Downs SH, Black N. The feasibility of creating a checklist for the 
assessment of the methodological quality both of randomized and 
non-randomized studies of health care interventions. J Epidemiol 
Commun Health. 1998;52:377–84.
 13. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of 
patient outcomes to pharmacist interventions. Part I: systematic 
review and meta-analysis in diabetes management. Ann Pharma-
cother. 2007;41:1569–82.
 14. Donabedian A. The quality of care: How can it be assessed? 
JAMA. 1988;260(12):1743–8.
 15. Cooney D, Moon H, Liu Y, Miller RT, Perzynski A, Watts B, et al. 
A pharmacist based intervention to improve the care of patients 
with CKD: a pragmatic, randomized, controlled trial. Bio Med 
Central Nephrol. 2015;16(1):56.
 16. Pourrat X, Sipert AS, Gatault P, Sautenet B, Hay N, Guinard F, 
et al. Community pharmacist intervention in patients with renal 
impairment. Int J Clin Pharm. 2015;37(6):1172–9.
 17. Vessal G. Detection of prescription errors by a unit-based 
clinical pharmacist in a nephrology ward. Pharm World Sci. 
2010;32(1):59–65.
 18. Via-Sosa MA, Lopes N, March M. Effectiveness of a drug dos-
ing service provided by community pharmacists in polymedicated 
elderly patients with renal impairment—a comparative study. 
BMC Fam Pract. 2013;14:96.
 19. Gheewala PA, Peterson GM, Curtain CM, Nishtala PS, Hannan 
PJ, Castelino RL. Impact of the pharmacist medication review 
services on drug-related problems and potentially inappropriate 
prescribing of renally cleared medications in residents of aged 
care facilities. Drugs Aging. 2014;31(11):825–35.
 20. Staino C, Pilch N, Patel S, Trobaugh K, Fleming J, Meadows 
H, et al. Optimizing finite resources: pharmacist chart reviews 
in an outpatient kidney transplant clinic. J Am Pharm Assoc. 
2015;55(6):613–20.
 21. Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P. Identifi-
cation of drug-related problems in ambulatory chronic kid-
ney disease patients: a 6-month prospective study. J Nephrol. 
2012;25(5):782–8.
 22. Mousavi M, Dashti-Khavidaki S, Khalili H, Farshchi A, Gatmiri 
M. Impact of clinical pharmacy services on stress ulcer prophy-
laxis prescribing and related cost in patients with renal insuffi-
ciency. Int J pharm pract. 2013;21(4):263–9.
 23. Dashti-Khavidaki S, Khalili H, Shahverdi S, Abbasi MR, 
Lessan-Pezeshki M. The role of clinical pharmacy services in 
achieving treatment targets in Iranian haemodialysis patients. 
Singapore Med J. 2012;53(9):599–603.
 24. Holm H, Bjerke K, Holst L, Mathiesen L. Use of renal risk 
drugs in patients with renal impairment. Int J clin pharm. 
2015;37(6):1136–42.
 25. Chen LL. A preliminary review of the medication management 
service conducted by pharmacists in haemodialysis patients of 
Singapore General Hospital. Proceedings of Singapore Health-
care. 2013;22(2):103–6.
 26. Arrabal-Durán P, Durán-García ME, Ribed-Sánchez A, 
Hidalgo-Collazos P, Sanjurjo-Sáez M. Pharmaceutical interven-
tions in prescriptions for patients admitted with chronic renal 
failure. Nefrologia. 2014;34(6):710–5. https ://doi.org/10.3265/
Nefro logia .pre20 14.Jul.12541 .
 27. Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-
driven renal medication dosing intervention in a primary 
care patient-centered medical home. Pharmacotherapy. 
2014;34(12):1330–5.
 28. Belaiche S, Romanet T, Bell R, Calop J, Allenet B, Zaoui P. 
Pharmaceutical care in chronic kidney disease: experience at 
Grenoble University Hospital from 2006 to 2010. J Nephrol. 
2012;25(4):558.
 29. Castelino RL, Sathvik BS, Parthasarathi G, Gurudev KC, Shetty 
MS, Narahari MG. Prevalence of medication-related problems 
among patients with renal compromise in an Indian hospital. J 
Clin Pharm Ther. 2011;36(4):481–7.
 30. Dashti-Khavidaki S, Sharif Z, Khalili H, Badri S, Alimadadi 
A, Ahmadi F, et al. The use of pharmaceutical care to improve 
health-related quality of life in hemodialysis patients in Iran. Int 
J Clin Pharm. 2013;35(2):260–7.
 31. Ramadaniati HU, Anggriani Y, Wowor V, Rianti A. Drug-related 
problems in chronic kidneys disease patients in an Indonesian 
hospital: Do the problems really matter? Int J Pharm Phar Sci. 
2016;8(12):298–302.
 32. Qudah B, Albsoul-Younes A, Alawa E, Mehyar N. Role of clini-
cal pharmacist in the management of blood pressure in dialysis 
patients. Int J Clin Pharm. 2016;38(4):931–40.
 33. Geerts AF, Haan ND, Koning FH, Sterren TM, Weel CV, Vervoort 
GM, et al. A pharmacy medication alert system based on renal 
function in older patients. Br J Gen Pract. 2012;62(601):e525–9.
 34. Ohnishi J, Miyake A, Kuwatsuka K, Onoue Y, Lee M, Koyama 
T, et al. Effect of pharmacist management on serum hemoglobin 
levels with renal anemia in hemodialysis outpatients. Biol Pharm 
Bull. 2011;34(10):1609–12.
 35. Jiang SP, Zhu ZY, Wu XL, Lu XY, Zhang XG, Wu BH. Effective-
ness of pharmacist dosing adjustment for critically ill patients 
receiving continuous renal replacement therapy: a comparative 
study. Ther Clin Risk Manag. 2014;10(1):405–12.
665International Journal of Clinical Pharmacy (2019) 41:630–666 
1 3
 36. Cabello-Muriel A, Gascón-Cánovas JJ, Urbieta-Sanz E, 
Iniesta-Navalón C. Effectiveness of pharmacist interven-
tion in patients with chronic kidney disease. Int J Clin Pharm. 
2014;36(5):896–903.
 37. AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evalua-
tion of the impact of pharmaceutical care service on hospitalized 
patients with chronic kidney disease in Jordan. Int J Clin Pharm. 
2013;35(5):780–9.
 38. Jiang SP, Zhu ZY, Ma KF, Zheng X, Lu XY. Impact of pharmacist 
antimicrobial dosing adjustments in septic patients on continuous 
renal replacement therapy in an intensive care unit. Scand J Infect 
Dis. 2013;45(12):891–9.
 39. Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara 
IQ, Smith KJ, et al. Impact of pharmacist-managed erythropoiesis-
stimulating agents clinics for patients with non-dialysis-dependent 
CKD. Am J Kidney Dis. 2012;60(3):371–9.
 40. Jiang SP, Xu YY, Yang P, Wu WF, Zhang XG, Lu XY, et al. Improv-
ing antimicrobial dosing in critically ill patients receiving continu-
ous venovenous hemofiltration and the effect of pharmacist dosing 
adjustment. Eur J Intern Med. 2014;25(10):930–5.
 41. Aberger EW, Migliozzi D, Follick MJ, Malick T, Ahern DK. 
Enhancing patient engagement and blood pressure management for 
renal transplant recipients via home electronic monitoring and web-
enabled collaborative care. Telemed J E Health. 2014;20(9):850–4.
 42. Adibe MO, Igboeli NU, Ukwe CV. Evaluation of drug therapy prob-
lems among renal patients receiving care in some tertiary hospitals 
in Nigeria. Trop J Pharm Res. 2017;16(3):697–704.
 43. Kelly CJ, Booth G. Pharmacist-led structured care for patients with 
diabetic nephropathy. Br J Diabetes Vasc Dis. 2008;8(2):86–8.
 44. Debenito JM, Billups SJ, Tran TS, Price LC. Impact of a clinical 
pharmacy anemia management service on adherence to monitoring 
guidelines, clinical outcomes, and medication utilization. J Manag 
Care Spec Pharm. 2014;20(7):715–20.
 45. Chang AR, Evans M, Yule C, Bohn L, Young A, Lewis M, et al. 
Using pharmacists to improve risk stratification and management of 
stage 3A chronic kidney disease: a feasibility study. BMC Nephrol. 
2016;17(1):168.
 46. Patricia NJ, Foote EF. A pharmacy-based medication reconciliation 
and review program in hemodialysis patients: a prospective study. 
Pharm Pract. 2016;14(3):785. https ://doi.org/10.18549 /Pharm pract 
.2016.03.785.
 47. Joost R, Dörje F, Schwitulla J, Eckardt KU, Hugo C. Intensified 
pharmaceutical care is improving immunosuppressive medication 
adherence in kidney transplant recipients during the first post-trans-
plant year: a quasi-experimental study. Nephrol Dial Transplant. 
2014;29(8):1597–607.
 48. Santschi V, Lord A, Berbiche D, Lamarre D, Corneille L, 
Prud’homme L, et al. Impact of collaborative and multidisciplinary 
care on management of hypertension in chronic kidney disease out-
patients. J Pharm Health Serv Res. 2011;2(2):79–87.
 49. Venkateswararao S, Asha Sara S, Kshama I, Rama P. Evaluation 
and pharmacists intervention for improving adherence among renal 
failure patients. Int J Pharm Pharm Sci. 2015;7(3):82–5.
 50. Rani V, Soundararajan P, Samyuktha CH, Kannan G, Thennarasu 
P. Impact of clinical pharmacist provided education on medication 
knowledge and adherence of hemodialysis patients in a South Indian 
university hospital. Asian J Pharm Clin Res. 2013;6:24–7.
 51. Dashti-Khavidaki S, Khalili H, Hamishekar H, Shahverdi S. Clini-
cal pharmacy services in an Iranian teaching hospital: a descriptive 
study. Pharm World Sci. 2009;31(6):696–700.
 52. Chia B, Cheen M, Gwee X, Chia BY, Cheen MH, Gwee XY, et al. 
Outcomes of pharmacist-provided medication review in collabora-
tive care for adult Singaporeans receiving hemodialysis. Int J Clin 
Pharm. 2017;39:1031–8.
 53. Mateti U, Nagappa A, Attur R, Nagaraju SP, Rangaswamy D. Impact 
of pharmaceutical care on the health-related quality of life among 
hemodialysis patients–a multicenter randomized controlled study. 
Saudi J Kidney Dis Transpl. 2017;28(6):1293–306.
 54. Anderegg M, Gums T, Uribe L, MacLaughlin EJ, Hoehns J, Bazal-
dua OV, et al. Pharmacist intervention for blood pressure control in 
patients with diabetes and/or Chronic Kidney Disease. Pharmaco-
therapy. 2018;38:309–18.
 55. Mateti U, Nagappa A, Attur R, Nagaraju SP, Rangaswamy D. Impact 
of pharmaceutical care on clinical outcomes among hemodialysis 
patients: a multicenter randomized controlled study. Saudi J Kidney 
Dis Transpl. 2018;29:801.
 56. Mateti U, Nagappa A, Attur R, Nagaraju SP, Rangaswamy D. Cost-
effectiveness of pharmaceutical care on patients undergoing main-
tenance hemodialysis—a multicenter randomized controlled study. 
Postgrad Med. 2018;130(7):621–6.
 57. Tuttle K, Alicic R, Short R, Neumiller JJ, Gates BJ, Daratha KB, 
et al. Medication therapy management after hospitalization in CKD: 
a randomized clinical trial. Clin J Am Soc Nephrol. 2018;13:231–
41.https ://doi.org/10.2215/cjn.06790 617.
 58. Xu X, Feng Y, Tian Y, Wang H. Pharmaceutical care in kidney 
transplant recipients: behavioral and physiologic outcomes at 12 
months. Transpl Proc. 2018;50(8):2451–6.
 59. Alshamrani M, Almalki A, Qureshi M, Yusuf O, Ismail S. Polyp-
harmacy and medication-related problems in hemodialysis patients: 
a call for deprescribing. Pharmacy. 2018;6:76–85.
 60. Chandrasekhar D, Ganesan V, Sreekumar S, Pradeep A, Geoji AS, 
George AE, et al. Impact of intensified pharmaceutical interventions 
in medication adherence in chronic kidney disease patients. J Young 
Pharm. 2018;10(2):208–12.
 61. Imamura Y, Takahashi Y, Hayashi T, Iwamoto M, Nakamura R, 
Goto M, et al. Usefulness of multidisciplinary care to prevent wors-
ening renal function in chronic kidney disease. Clin Exp Nephrol. 
2018;19:1–9.
 62. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and 
their role in evidence-based medicine. Plast Reconstr Surg. 
2011;128(1):305–10.
 63. Mahboobi H, Khorgoei T, Bansal N. Designing, conducting and 
reporting randomised controlled trials: a few key points. ISBN: 978-
953-51-0504-6, In Tech 2012. http://www.intec hopen .com/books 
/evide nce-based -medic ine-close r-to-patie nts-or-scien tists -/desig 
ningc onduc ting-and-repor ting-rtcs-key-point s. Accessed 12 Feb 
2018.
 64. Salgado TM, Correr CJ, Moles R, Benrimoj SI, Fernandez-Llimos F. 
Assessing the implementability of clinical pharmacist interventions 
in patients with chronic kidney disease: an analysis of systematic 
reviews. Ann Pharmacother. 2013;47(11):1498–506.
 65. Schroter S, Glasziou P, Heneghan C. Quality of descriptions of 
treatments: a review of published randomised controlled trials. BMJ 
Open. 2012;2:e001978.
 66. Correr CJ, Melchiors AC, Souza TT, Rotta I, Salgado TM, Fernan-
dez-Llimos F. A tool to characterize the components of pharmacist 
interventions in clinical pharmacy services: the DEPICT Project. 
Ann Pharmacother. 2013;47:946–52. https ://doi.org/10.1345/
aph.1S006 .
 67. Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate 
prescribing in chronic kidney disease: a systematic review of preva-
lence, associated clinical outcomes and impact of interventions. Int 
J Clin Pract. 2017. https ://doi.org/10.1111/ijcp.12960 .
 68. Peterson GM, Jackson SL, Fitzmaurice KD, Gee PR. Attitudes 
of Australian pharmacists towards practice-based research. J 
Clin Pharm Ther. 2009;34(4):397–405. https ://doi.org/10.111
1/j.1365-2710.2008.01020 .x.
 69. Awaisu A, Alsalimy N. Pharmacists’ involvement in and attitudes 
towards pharmacy practice research: a systematic review of the 
literature. Res Social Adm Pharm. 2014. https ://doi.org/10.1016/j.
sapha rm.2014.12.008.
666 International Journal of Clinical Pharmacy (2019) 41:630–666
1 3
 70. Esposito P, Dal Canton A. Clinical audit, a valuable tool to improve 
quality of care: general methodology and applications in nephrol-
ogy. World J Nephrol. 2014;3(4):249–55. https ://doi.org/10.5527/
wjn.v3.i4.249.
 71. Beuscart JB, Knol W, Cullinan S, Schneider C, Dalleur O, Boland 
B, et al. International core outcome set for clinical trials of medica-
tion review in multi-morbid older patients with polypharmacy. BMC 
Med. 2018;16(1):21–9.
 72. Lombardi N, Wei L, Ghaleb M, Pasut E, Leschiutta S, Rossi P, et al. 
Evaluation of the implementation of a clinical pharmacy service on 
an acute internal medicine ward in Italy. BMC Health Serv Res. 
2018;18:259. https ://doi.org/10.1186/s1291 3-018-2988-y.
 73. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, 
Brookes ST, et al. The COMET handbook: version 1.0. Trials 
2017;18(Suppl 3):280.
 74. Rankin A, Cadogan CA, Ryan C, Clyne B, Smith SM, Hughes CM, 
et al. Core outcome set for trials aimed at improving appropriate 
polypharmacy in older people in primary care. J Am Geriatr Soc. 
2018. https ://doi.org/10.1111/jgs.15245 .
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
